全文获取类型
收费全文 | 24522篇 |
免费 | 1354篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 390篇 |
儿科学 | 561篇 |
妇产科学 | 655篇 |
基础医学 | 3453篇 |
口腔科学 | 2116篇 |
临床医学 | 1642篇 |
内科学 | 5069篇 |
皮肤病学 | 464篇 |
神经病学 | 2383篇 |
特种医学 | 649篇 |
外科学 | 2835篇 |
综合类 | 59篇 |
一般理论 | 8篇 |
预防医学 | 2159篇 |
眼科学 | 550篇 |
药学 | 1874篇 |
中国医学 | 180篇 |
肿瘤学 | 895篇 |
出版年
2023年 | 205篇 |
2022年 | 262篇 |
2021年 | 691篇 |
2020年 | 412篇 |
2019年 | 652篇 |
2018年 | 1034篇 |
2017年 | 733篇 |
2016年 | 724篇 |
2015年 | 742篇 |
2014年 | 874篇 |
2013年 | 1269篇 |
2012年 | 2128篇 |
2011年 | 2375篇 |
2010年 | 1162篇 |
2009年 | 782篇 |
2008年 | 1710篇 |
2007年 | 1668篇 |
2006年 | 1501篇 |
2005年 | 1379篇 |
2004年 | 1326篇 |
2003年 | 1094篇 |
2002年 | 848篇 |
2001年 | 352篇 |
2000年 | 365篇 |
1999年 | 259篇 |
1998年 | 119篇 |
1997年 | 89篇 |
1996年 | 72篇 |
1995年 | 58篇 |
1994年 | 52篇 |
1993年 | 47篇 |
1992年 | 76篇 |
1991年 | 71篇 |
1990年 | 51篇 |
1989年 | 50篇 |
1988年 | 51篇 |
1987年 | 36篇 |
1986年 | 41篇 |
1985年 | 68篇 |
1984年 | 41篇 |
1983年 | 25篇 |
1982年 | 25篇 |
1981年 | 36篇 |
1980年 | 34篇 |
1978年 | 33篇 |
1977年 | 24篇 |
1974年 | 28篇 |
1971年 | 25篇 |
1970年 | 26篇 |
1969年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
J. Magalhães I.O. Gonçalves J. Lumini-Oliveira I. Marques-Aleixo E. Passos S. Rocha-Rodrigues N.G. Machado A.C. Moreira D. Rizo G. Viscor P.J. Oliveira J.R. Torrella A. Ascensão 《International journal of cardiology》2014
Background
Modulation of the mitochondrial permeability transition pore (MPTP) and inhibition of the apoptotic signaling are critically associated with the cardioprotective phenotypes afforded by both intermittent hypobaric-hypoxia (IHH) and endurance-training (ET). We recently proposed that IHH and ET improve cardiac function and basic mitochondrial capacity, although without showing addictive effects. Here we investigate whether a combination of IHH and ET alters cardiac mitochondrial vulnerability to MPTP and related apoptotic signaling.Methods
Male Wistar rats were divided into normoxic-sedentary (NS), normoxic-exercised (NE, 1 h/day/5 week treadmill-running), hypoxic-sedentary (HS, 6000 m, 5 h/day/5 weeks) and hypoxic-exercised (HE) to study susceptibility to calcium-induced cardiac MPTP opening. Mitochondrial cyclophilin D (CypD), adenine nucleotide translocator (ANT), Bax and Bcl-2 protein contents were semi-quantified by Western blotting. Cardiac caspase 3-, 8- and 9-like activities were measured. Mitochondrial aconitase and superoxide dismutase (MnSOD) activity and malondialdehyde (MDA) and sulphydryl group (–SH) content were determined.Results
Susceptibility to MPTP decreased in NE and HS vs. NS and even further in HE. The ANT content increased in HE vs. NS. Bcl-2/Bax ratio increased in NE and HS compared to NS. Decreased activities in tissue caspase 3-like (HE vs. NS) and caspase 9-like (HS and HE vs. NS) were observed. Mitochondrial aconitase increased in NE and HS vs. NS. No alterations between groups were observed for caspase 8-like activity, MnSOD, CypD, MDA and –SH.Conclusions
Data confirm that IHH and ET modulate cardiac mitochondria to a protective phenotype characterized by decreased MPTP induction and apoptotic signaling, although without visible addictive effects as initially hypothesized. 相似文献992.
993.
Luciano Consuegra-Sánchez Antonio Melgarejo-Moreno José Galcerá-Tomás Nuria Alonso-Fernández Angela Díaz-Pastor Germán Escudero-García Leticia Jaulent-Huertas Marta Vicente-Gilabert 《Revista espa?ola de cardiología》2014
Introduction and objectives
Patients with a current acute coronary syndrome and previous ischemic heart disease, peripheral arterial disease, or cerebrovascular disease are reported to have a poorer outcome than those without these previous conditions. It is uncertain whether this association with outcome is observed at long-term follow-up.Methods
Prospective observational study, including 4247 patients with ST-segment elevation myocardial infarction. Detailed clinical data and information on previous ischemic heart disease, peripheral arterial disease, and cerebrovascular disease («vascular burden») were recorded. Multivariate models were performed for in-hospital and long-term (median, 7.2 years) all-cause mortality.Results
One vascular territory was affected in 1131 (26.6%) patients and ≥ 2 territories in 221 (5.2%). The total in-hospital mortality rate was 12.3% and the long-term incidence density was 3.5 deaths per 100 patient-years. A background of previous ischemic heart disease (odds ratio = 0.83; P = .35), peripheral arterial disease (odds ratio = 1.30; P=.34), or cerebrovascular disease (stroke) (odds ratio = 1.15; P = .59) was not independently predictive of in-hospital death. In an adjusted model, previous cerebrovascular disease and previous peripheral arterial disease were both predictors of mortality at long-term follow-up (hazard ratio = 1.57; P < .001; and hazard ratio = 1.34; P = .001; respectively). Patients with ≥ 2 diseased vascular territories showed higher long-term mortality (hazard ratio = 2.35; P < .001), but not higher in-hospital mortality (odds ratio = 1.07; P = .844).Conclusions
In patients with a diagnosis of ST-segment elevation acute myocardial infarction, the previous vascular burden determines greater long-term mortality. Considered individually, previous cerebrovascular disease and peripheral arterial disease were predictors of mortality at long-term after hospital discharge.Full English text available from: www.revespcardiol.org/en 相似文献994.
Pedro Gabriel Melo de Barros e Silva Otavio Berwanger Elizabete Silva dos Santos Antnio Carlos Sobral Sousa Margaret Assad Cavalcante Pedro Beraldo de Andrade Fernando Carvalho Neuenschwander Hugo Vargas Filho Jorge Ilha Guimares Jadelson Andrade Angelo Amato Vincenzo de Paola Marcus Vinicius Bolivar Malachias Luiz Alberto Piva e Mattos Dalton Bertolim Precoma Fernando Bacal Oscar Pereira Dutra 《Arquivos brasileiros de cardiologia》2020,114(6):995
995.
Ingrid de Siqueira Pereira Marta Marques Maia Allecineia Bispo da Cruz João Paulo Marochi Telles Jose Ernesto Vidal Ricardo Gava Cristina Silva Meira-Strejevitch Vera Lucia Pereira-Chioccola 《Parasite immunology》2020,42(4):e12696
This study investigated the potential of five miRNA candidates for cerebral toxoplasmosis/HIV co-infection (CT/HIV) biomarkers. miR-155-5p, miR-146a-5p, miR-21-5p, miR-125b-5p and miR-29c-3p were tested in 79 plasma divided into groups: 32 CT/HIV patients; 27 individuals with asymptomatic toxoplasmosis (AT); and 20 individuals seronegative for toxoplasmosis (NC). From each was collected peripheral blood/EDTA for laboratory diagnosis. Blood cells for DNA extractions (molecular diagnosis), plasma for RNA extractions (gene expression) and ELISA (serological diagnosis). miRNA expression was performed by qPCR, and values were expressed in Relative Quantification (RQ). Among the five miRNAs, miR-21-5p and miR-146a-5p were up-expressed in CT/HIV group when compared with AT and NC groups. RQ means for miR-21-5p and miR-146a-5p in CT/HIV group were 3.829 and 2.500, while in AT group, were 1.815 and 1.661, respectively. Differences between 3 groups were statistically significant (Kruskal-Wallis ANOVA test), as well as CT/HIV and AT groups (Mann-Whitney test). Plasma of CT/HIV and AT groups expressed similar levels of miR-29c-3p, miR-155-5p and miR-125b-5p. As NC group was different of CT/HIV and AT groups, differences between three groups were statistically significant (Kruskal-Wallis ANOVA test). No difference was shown between CT/HIV and AT groups (Mann-Whitney test). These results suggest the host miRNAs modulation by Toxoplasma gondii. 相似文献
996.
Palma Paulo Jorge Messias Ana Cerqueira António Rosa Tavares Luís Diogo Caramelo Francisco Roseiro Luís Santos João Miguel 《Odontology / the Society of the Nippon Dental University》2019,107(3):324-332
Odontology - To evaluate the effect of immersion in 3% sodium hypochlorite solution in the resistance to cyclic fatigue of three nickel–titanium (NiTi) rotary file systems, ProTaper Next... 相似文献
997.
998.
Andersen Jeppe D. Meyer Olivia S. Simão Filipa Jannuzzi Juliana Carvalho Elizeu Andersen Mikkel M. Pereira Vania Børsting Claus Morling Niels Gusmão Leonor 《International journal of legal medicine》2020,134(5):1569-1579
International Journal of Legal Medicine - Although many genes have been shown to be associated with human pigmentary traits and forensic prediction assays exist (e.g. HIrisPlex-S), the genetic... 相似文献
999.
Stefano Molica Diana Giannarelli Luciano Levato Rosanna Mirabelli Massimo Gentile Mirella Lentini Fortunato Morabito 《International journal of hematology》2014,100(3):290-295
We propose an algorithm based on a slightly modified version of MD Anderson Cancer Center (MDACC) score (i.e., mutational status of IgVH, LDH, presence of high-risk FISH abnormalities), β2-microglobulin and separation of clinical monoclonal B-cell lymphocytosis (cMBL) from chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT) of a prospective multicentre cohort including 83 cMBL and 136 CLL Rai stage 0 patients. Patients with MDACC score point ≥38, at any level of β2-microglobulin and irrespective of whether they fulfilled 2008 International Workshop on CLL (IWCLL) criteria for CLL Rai stage 0 or cMBL, experienced the worst clinical outcome (5-year TTFT, 24 %) and formed the high-risk group. In contrast, subjects with a diagnosis of cMBL, MDACC score point <38 and β2-microglobulin ≤ UNL had the best clinical outcome (5-year TTFT, 100 %) and constituted the low-risk group. The intermediate group included patients in Rai stage 0, MDACC score point <38, and any level of β2-microglobulin, and patients with cMBL, MDACC score point <38, and β2-microglobulin ≥ UNL. Cases showing these features can be grouped together to form the intermediate-risk group (5-year TTFT, 65 %). Although the separation between cMBL and Rai stage 0, as proposed by the 2008 IWCLL guidelines, has clinical implications, the model we propose may help to classify patients with cMBL and Rai stage 0 into more precise subgroups suggesting that a prognostic separation of these entities based solely on clonal B-cell threshold may be unsatisfactory. 相似文献
1000.
Manuel Cappellari Giuseppe Moretto Nicola Micheletti Francesco Donato Giampaolo Tomelleri Giosuè Gulli Monica Carletti Giovanna Maddalena Squintani Tiziano Zanoni Sarah Ottaviani Silvia Romito Giorgio Tommasi Anna Maria Musso Luciano Deotto Giuseppe Gambina Domenico Sergio Zimatore Paolo Bovi 《Journal of thrombosis and thrombolysis》2014,37(4):549-556
According to current European Alteplase license, therapeutic-window for intravenous (IV) thrombolysis in acute ischemic stroke has recently been extended to 4.5 h after symptoms onset. However, due to numerous contraindications, the portion of patients eligible for treatment still remains limited. Early neurological status after thrombolysis could identify more faithfully the impact of off-label Alteplase use that long-term functional outcome. We aimed to identify the impact of off-label thrombolysis and each off-label criterion on early clinical outcomes compared with the current European Alteplase license. We conducted an analysis on prospectively collected data of 500 consecutive thrombolysed patients. The primary outcome measures included major neurological improvement (NIHSS score decrease of ≤8 points from baseline or NIHSS score of 0) and neurological deterioration (NIHSS score increase of ≥4 points from baseline or death) at 24 h. We estimated the independent effect of off-label thrombolysis and each off-label criterion by calculating the odds ratio (OR) with 2-sided 95 % confidence interval (CI) for each outcome measure. As the reference, we used patients fully adhering to the current European Alteplase license. 237 (47.4 %) patients were treated with IV thrombolysis beyond the current European Alteplase license. We did not find significant differences between off- and on-label thrombolysis on early clinical outcomes. No off-label criteria were associated with decreased rate of major neurological improvement compared with on-label thrombolysis. History of stroke and concomitant diabetes was the only off-label criterion associated with increased rate of neurological deterioration (OR 5.84, 95 % CI 1.61–21.19; p = 0.024). Off-label thrombolysis may be less effective at 24 h than on-label Alteplase use in patients with previous stroke and concomitant diabetes. Instead, the impact of other off-label criteria on early clinical outcomes was not different compared with current European Alteplase license. 相似文献